RxDoctor Payments Data

Jenny Mackrill

Family · Des Moines, IANPI 1205477684

Payments from drug & device makers

$1,101in general payments, 2019–2025

Across 40 payments — averaging $27.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$354
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$233
  • Madrigal Pharmaceuticals$164
  • Ipsen Biopharmaceuticals, Inc$146
  • Intercept Pharmaceuticals, Inc.$89
  • AbbVie$55
  • plus $59 from 3 others

What the payments were for

  • Food & beverage$1,101100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,101 in reported general payments places this provider in the 80th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$22,585
Medicare patients
107
Services billed
309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin29$93,930
VemlidyTenofovir Alafenamide16$23,804
Ursodiol38$4,665
Azathioprine32$2,250
Lactulose85$1,102
Tenofovir Disoproxil Fumarate11$812
Pantoprazole Sodium75$759
Nadolol17$552
Omeprazole29$465
Spironolactone40$311
Rosuvastatin Calcium12$123
Prednisone15$102
Furosemide40$91
Simvastatin13$79
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$14

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$233$93,93029 claims
GileadVemlidy$354$23,80416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,268 family providers in Iowa.

Other family in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →